In 2018, the FDA approved CBD for use as an ingredient in Epidiolex, which is a prescription drug indicated for the treatment of severe epilepsy. Participants in the hemp industry have stated that drug approval is what’s keeping the FDA from regulating CBD as a dietary ingredient or supplement. Minor cannabinoids may not face the same issues as CBD because they haven’t been approved as prescription medications. Many hope the FDA’s approach to major and minor cannabinoids will shift, depending on the laws that make marijuana legal on a federal scale. A few manufacturers and leaders involved in the hemp industry were asked for their thoughts on how minor cannabinoids such as CBC, CBN, and CBG could be impacted by the Food and Drug Administration’s passivity on CBD and what would happen if marijuana was legalized federally. Hemp Industries Association president Mike Lewis stated that the FDA’s refusals were based on the fact that CBD was an active ingredient in Epidiolex, which meant that many hemp cannabinoids shouldn’t be subject to the reclusion provision of the Federal Food, Drug, and Cosmetic’s Act.

CannabisNewsWire, 09/20/2021 16:20:00

Open article: